middle.news
PYC Therapeutics Advances Dosing in Polycystic Kidney Disease Trial
1:43am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
PYC Therapeutics Advances Dosing in Polycystic Kidney Disease Trial
1:43am on Monday 2nd of June, 2025 AEST
Key Points
Safety Review Committee approves dose increase from 0.4 mg/kg to 1.2 mg/kg
Dosing in healthy volunteers progressing as planned in Phase 1a Single Ascending Dose study
Patient dosing for PKD expected to begin in the second half of 2025
Phase 1a/1b studies to be followed by registrational Phase 2/3 trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC
OPEN ARTICLE